Current Releases

bullet CONTOUR® NEXT LINK 2.4 FROM ASCENSIA DIABETES CARE, THE FIRST PMA-APPROVED BGMS, FEATURED IN U.S. LAUNCH OF MINIMED® 670G HYBRID CLOSED LOOP SYSTEM BY MEDTRONIC

Parsippany, June 6, 2017
Ascensia Diabetes Care today announced the commercial launch by Medtronic of the MiniMed® 670G system in the United States. The MiniMed® 670G system is the first Hybrid Closed Loop (HCL) insulin delivery system to be approved anywhere in the world and exclusively features the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System (BGMS) from Ascensia Diabetes Care.

bulletASCENSIA DIABETES CARE RECEIVES FDA CLEARANCE FOR THE APP-ENABLED CONTOUR® NEXT ONE BLOOD GLUCOSE MONITORING SYSTEM

Parsippany, November 21, 2016
Ascensia Diabetes Care announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CONTOUR® NEXT ONE Blood Glucose Monitoring System (BGMS), marking a key step in making the next-generation system available to people living with diabetes in the U.S.

bulletASCENSIA DIABETES CARE LAUNCHES CONTOUR® NEXT LINK 2.4 WIRELESS BLOOD GLUCOSE MONITORING SYSTEM AS PART OF THE MEDTRONIC MINIMED® 630G SYSTEM WITH SMARTGUARD TECHNOLOGY

Parsippany, August 11, 2016
Ascensia Diabetes Care has today announced the commercial launch and approval from the U.S. Food and Drug Administration (FDA) of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System (BGMS) as part of the Medtronic MiniMed® 630G system with SmartGuard technology.

bulletBayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million

Leverkusen, June 10, 2015
Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation.